Physician profile
Morgan Knowles
NPI 1457088684
$1,480.14
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.57 · 2023: $643 · 2024: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.13 | 2023-2024 | Airsupra, Farxiga, Flumist Quadrivalent |
| Abbvie INC. | $164.34 | 2022-2024 | |
| Novo Nordisk INC | $149.67 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Idorsia Pharmaceuticals US INC | $149.67 | 2023 | Quviviq |
| Lilly USA, LLC | $110.47 | 2023-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.31 | 2023-2024 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $73.92 | 2023-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $59.53 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $48.67 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $47.73 | 2023-2024 | Contrave, Onzetra Xsail |
| Pfizer INC. | $45.98 | 2023-2024 | |
| Viiv Healthcare Company | $39.72 | 2024 | Apretude |
| Indivior INC. | $37.95 | 2023 | Sublocade |
| Merck Sharp & Dohme LLC | $35.20 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Boston Scientific Corporation | $30.01 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $26.40 | 2023 | Absorica Ld, Winlevi |
| Amgen INC. | $24.53 | 2023 | Prolia, Evenity |
| Astellas Pharma US INC | $21.35 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.15 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $18.69 | 2023 | Auvelity |
| Seqirus USA INC | $17.39 | 2024 | Fluad, Flucelvax |
| Lucid Diagnostics INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.